Jump to Main Content


J. Evan Sadler (1951-2018)

Evan Sadler, MD, PhD

J. Evan Sadler, MD, PhD, who served as president of ASH in 2011, pioneered the study of several blood coagulation factors. His contributions have been critical to the molecular, genetic, and biochemical characterization of von Willebrand factor and ADAMTS13, two proteins associated with bleeding and clotting disorders. His laboratory identified the molecular basis for a range of subtypes of the bleeding disorder von Willebrand disease (VWD), which has led to improved diagnosis and therapy. In addition, his complementary studies of ADAMTS13 structure and function have important implications for understanding the pathophysiology of thrombotic thrombocytopenic purpura, a rare clotting disorder. The molecular understanding of these diseases enabled Dr. Sadler to lead efforts to develop existing clinical guidelines for the diagnosis and treatment of VWD and TTP.

Dr. Sadler earned his PhD in biochemistry and his MD from Duke University in 1978 and 1979. He completed his postgraduate internship at Duke University before heading to the University of Washington in Seattle to complete his fellowship. He began his academic career at Washington University in St. Louis in 1984 and went on to serve on the faculty for 34 years. Dr. Sadler has previously been recognized by the ASH membership for his contributions to hematology, having been awarded the Henry M. Stratton Medal for Basic Science and the William Dameshek Prize.